Noticias y vídeos - EDWARDS LIFESCIENCES

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies...

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION PR Newswire SAN FRANCISCO, Oct. 26, 2023 SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with...

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif., Oct. 25, 2023 IRVINE, Calif. , Oct. 25, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 percent to $1.48 billion ; constant currency 1 sales grew 11 percent Q3 TAVR sales grew 11 percent; constant currency sales grew 10 percent Q3 EPS of $0.63 ; adjusted 1 EPS of $0.59 Received CE Mark for EVOQUE,...

FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE PR Newswire SAN FRANCISCO, Oct. 24, 2023 SAN FRANCISCO , Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and rehospitalization at five years. These data, which represent the longest clinical follow-up for a low surgical risk cohort of transcatheter...

EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK PR Newswire IRVINE, Calif., Oct. 19, 2023 IRVINE, Calif. , Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR). The EVOQUE system is the world's first transcatheter valve replacement therapy to receive regulatory approval...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023 PR Newswire IRVINE, Calif., Oct. 18, 2023 IRVINE, Calif. , Oct. 18, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on Wednesday, October 25, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The...

BetterInvesting™ Magazine Update on Edwards Lifesciences Corp. and 3M Company PR Newswire TROY, Mich., Aug. 29, 2023 TROY, Mich. , Aug. 29, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Edwards Lifesciences Corp. (NYSE:EW) as its "Stock to Study" and 3M Company (NYSE:MMM) as its "Undervalued Stock" in the November 2023 issue for investors' informational and educational use. "Too many novice investors still don't realize...

EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire IRVINE, Calif., Aug. 28, 2023 IRVINE, Calif. , Aug. 28, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7 , 2023. Bernard Zovighian, chief executive officer, and Scott B. Ullem , chief financial officer, are scheduled to speak to conference attendees at 11:00 a.m. ET . A live...

EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS PR Newswire IRVINE, Calif., July 26, 2023 IRVINE, Calif. , July 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent to $1.53 billion ; constant currency 1 sales grew 12 percent All product groups achieved double digit constant currency sales growth in Q2 Q2 TAVR sales grew 9 percent; constant currency sales grew 10 percent...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023 PR Newswire IRVINE, Calif., July 19, 2023 IRVINE, Calif. , July 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday, July 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will...

Edwards Lifesciences annonce aujourd'hui les résultats du registre EU-HYPROTECT indiquant que l'utilisation du logiciel Acumen HPI peut contribuer à réduire la durée et la gravité de l'hypotension peropératoire chez les patients subissant une chirurgie non cardiaque. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : https://www.businesswire.com/news/home/20230608005568/fr/ (Graph: Business Wire) EU-HYPROTECT est un registre d'observation...

DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY PR Newswire PARIS, May 17, 2023 PARIS , May 17, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical...

EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA PR Newswire LOS ANGELES, May 7, 2023 LOS ANGELES , May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative RESILIA tissue. The data, which represent the longest clinical follow-up for Edwards'...

EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS PR Newswire IRVINE, Calif., April 26, 2023 IRVINE, Calif. , April 26, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2023 . Highlights and Outlook Q1 sales grew 9 percent to $1.46 billion ; constant currency 1 sales grew 13 percent Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent Q1 EPS of $0.56 ; adjusted 1 EPS of $0.62 Repurchased approximately $250...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON APRIL 26, 2023 PR Newswire IRVINE, Calif., April 19, 2023 IRVINE, Calif. , April 19, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2023 after the market closes on Wednesday, April 26, 2023 , and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call...

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS PR Newswire NEW ORLEANS, March 6, 2023 NEW ORLEANS , March 6, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data. Together these studies, presented at...

EDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS PR Newswire IRVINE, Calif., Jan. 31, 2023 IRVINE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook Q4 sales grew 1 percent to $1.35 billion ; constant currency 1 sales grew 7 percent Q4 TAVR sales were flat; constant currency sales grew 5 percent Q4 EPS of $0.65 ; adjusted 1 EPS increased 25 percent to $0.64 2022 sales of $5.38...

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 31, 2023 PR Newswire IRVINE, Calif., Jan. 24, 2023 IRVINE, Calif. , Jan. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW ) plans to announce its operating results for the quarter ended December 31, 2022 after the market closes on Tuesday, January 31, 2023 , and will host a conference call at 5:00 p . m . ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The...

EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE PR Newswire IRVINE, Calif., Jan. 5, 2023 IRVINE, Calif. , Jan. 5, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 , 2023. Michael A. Mussallem, chairman and chief executive officer, is scheduled to present at 11:15 a.m. PT . Bernard Zovighian, president and incoming chief executive officer, and Scott...

EDWARDS LIFESCIENCES ANUNCIA DONACIONES POR MÁS DE $330 MIL A DIEZ ORGANIZACIONES BENÉFICAS EN COSTA RICA A TRAVÉS DE SU FUNDACIÓN PR Newswire SAN JOSÉ, Costa Rica, 22 de diciembre de 2022 SAN JOSÉ, Costa Rica , 22 de diciembre de 2022 /PRNewswire/ -- El día de hoy, Edwards Lifesciences anunció que la fundación Edwards Lifesciences Foundation ha donado más de US$330 mil a diez organizaciones benéficas que brindan ayuda en Costa Rica , como parte de su compromiso para mejorar las vidas...